Procurement of Infant Incubator 3 Lots : Lot 1 - 2,029 units, Lot 2 - 2,594 units, Lot 3 - 2,386 units
Procurement of Infant Incubator 3 Lots : Lot 1 - 2,029 units, Lot 2 - 2,594 units, Lot 3 - 2,386 units
Don't miss the next one like this
New health grants in Indonesia open all the time. Get a free weekly email with only the ones that match — nothing else.
Want help winning this?
Enter your email and we'll send the official application link, deadlines and pointers right away — free. Want a hand? Tick the box and we'll introduce you to a vetted grant or bid writer. The intro's free, and you only pay if you choose to work with them.
Related opportunities
See all alternatives →More grants — Health · Indonesia
Procurement of High Pressure Steam Sterilizer (Autoclave) 3 Lots (Contract) : Lot 1 - 1,270 units , Lot 2 - 2,118 units , Lot 3 - 2,103 units
→Procurement of High Pressure Steam Sterilizer (Autoclave) 3 Lots (Contract) : Lot 1 - 1,270 units , Lot 2 - 2,118 units , Lot 3 - 2,103 units
TenderCloses 2026-10-29IndonesiaHealthProcurement of Dental Chair II 4 Lots : Lot 1 - 936 units, Lot 2 - 742 Units, Lot 3 - 708 Units, Lot 4 - 841 Units
→Procurement of Dental Chair II 4 Lots : Lot 1 - 936 units, Lot 2 - 742 Units, Lot 3 - 708 Units, Lot 4 - 841 Units
TenderCloses 2026-11-02IndonesiaHealthProcurement of Vaccine Refrigerator (Lemari Pendingin Vaksin) 1.872 unit
→Procurement of Vaccine Refrigerator (Lemari Pendingin Vaksin) 1.872 unit
TenderCloses todayIndonesiaHealthDecode the Immunoscience of age-related diseases
→Expected Impact: The action under this topic is expected to achieve the following impacts: Accelerate EU access to more cost-effective interventions in an increasingly ageing population by identifying personalised treatment approaches for elderly-onset immune diseases. Decrease disease risk later in life by defining specific prevention strategies based on ageing biomarkers and risk factors. Halt age-associated disease exacerbation by the identification of predictive and digital biomarkers that can stratify patients for early intervention. Improve quality of life for healthy individuals and patients by preventing further health decline, avoiding escalating care costs, and properly stratifying individuals earlier in the diagnostic pathway. Accelerate adoption of innovative diagnostic, preventative, and therapeutic strategies, strengthening the EU’s position as a healthcare innovator. Evaluate digital biomarker as potential regulatory endpoints in the ultimate goal to develop medicines for ‘healthy ageing’. Integrate fragmented research efforts by bringing together health industry sectors and stakeholders to develop clinical and multi-omics data integration capabilities. Enable new…
Grant$10.7MCloses in 14 daysEUHealthNeutral-Atom Platform Technologies
→Expected Outcome: This action aims to establish European leadership in neutral-atom quantum simulation and digital quantum computing by delivering: Fully programmable industry-ready quantum simulators based on 10.000 neutral atoms in a scalable architecture, accessible via cloud platforms, and with the possibility of integrating them into high-performance computing environments. Fully programmable platform for neutral-atom quantum computing capable of both analogue quantum operations and gate-based computing with 1.000 physical qubits and a clear path to further scalability to 10.000 physical qubits. Coherence time of the order of hundreds of interaction times and infidelity of operations below 1%. Demonstration of quantum simulation and/or computing operating beyond classical computability, validated through benchmarking with classical methods. New real-world applications across science and industry (at least two) (e.g: in the energy and health sectors) The software stack for these applications, including enhanced software for verification, algorithm implementation, and user programming interfaces. Demonstration of the full quantum stack – including quantum control, electronic…
Grant$22.8MCloses 2026-11-17EUHealthAn AI Foundation Toxicology Model and Framework to Support Waiving a Second Species in Drug Safety Studies
→Expected Impact: The action under this topic is expected to achieve the following impacts: Faster and more informed decision-making through the use of an AI-driven NAM (AI Foundation Toxicology Model) and increased efficiency through rapid processing of vast amounts of data [1] . Increased consistency and standardisation in a NAM-based approach, specifically an AI model, used by industry in the efficient development, testing and production of safe and effective innovative health technologies, improving industrial competitiveness. Regulatory adoption of a NAM-enabled second species waiver model (AI Foundation Toxicology Model) and weight-of-evidence framework, in line with recommendations and more consistent global decision-making on waiving second species testing. Reduction in animal use, accelerated timelines and lower costs, enhancing the competitiveness of the European health industry through economical and ethical benefits. Improved public health as patients will benefit from safe and effective medicines developed faster using validated NAMs. The action is expected to contribute to the EU Directive (2010/63/EU) [2] on the protection of animals used for scientific purposes and…
Grant$10.5MCloses in 14 daysEUHealth
Always confirm details on the official source before applying — see our methodology.